|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to first investigate the expression of seven different PC-related RNAs that included serine 2 (TMPRSS2): erythroblastosis virus E26 oncogene homolog (ERG) gene (TMPRSS2-ERG, T2E) fusion, alpha-methylacyl-CoA racemase (AMACR), kallikrein related peptidase 3 (KLK3), androgen receptor (AR), prostate cancer specific antigen 3 (PCA3), and matrix metalloproteinases (MMP)-2 and 9.
|
30294801 |
2019 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancer progression is driven by genome instability incurred rearrangements such as transmembrane protease, serine 2 (TMPRSS2)/v-ets erythroblastosis virus E26 oncogene (ERG) that could possibly turn some of the tumor suppressor micro-RNAs into pro-oncogenic ones.
|
28050800 |
2017 |
|
Erythroblastosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The TMPRSS2:E‑twenty‑six (ETS) gene fusion occurs frequently in a high proportion of patients with prostate cancer (PCa) in Western countries, and the aberrant expression of TMPRSS2: v‑ETS avian erythroblastosis virus E26 oncogene homolog (ERG), the most common form of the corresponding protein, can regulate cell migration and contribute to tumor invasion and metastasis.
|
26935606 |
2016 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphatase and tensin homolog (PTEN) gene aberration and trans membrane protease, serine 2 (TMPRSS2)-v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion are the most prevalent genomic events in prostate cancer.
|
26424596 |
2016 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
An early and common alteration is the gene fusion between the transmembrane protease serine 2 (TMPRSS2) gene and the v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) gene resulting in expression of the oncoprotein ERG.
|
27910803 |
2016 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on next-generation sequencing of early-onset prostate cancer (PCa), we earlier demonstrated that PCa in young patients is prone to rearrangements involving androgen-regulated genes-such as transmembrane protease, serine 2 (TMPRSS2)-v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) fusion-and provided data suggesting that this situation might be caused by increased androgen signaling in younger men.
|
25015038 |
2014 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since 2005, the presence of the genetic rearrangement between transmembrane-serine protease gene (TMPRSS2) and the erythroblast transformation-specific (ETS) member ERG (v-ets erythroblastosis virus E26 oncogene homolog avian) has been demonstrated in almost half of PCa cases.
|
23781502 |
2013 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whether the genomic rearrangement transmembrane protease, serine 2 (TMPRSS2):v-ets erythroblastosis virus E26 oncogene homolog (ERG) has prognostic value in prostate cancer is unclear.
|
22736790 |
2012 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To study the role of transmembrane protease, serine 2 (TMPRSS2)-v-ets erythroblastosis virus E26 oncogene homolog (ERG) fusion, an androgen-dependent growth factor, in circulating tumor cells (CTCs) as a biomarker of sensitivity to AA.
|
21802835 |
2011 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
|
19395877 |
2009 |
|
Erythroblastosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, gene fusions involving the prostate-specific gene transmembrane protease, serine 2 (TMPRSS2) and members of the erythroblastosis virus E26 transforming sequence (ETS) family of transcription factors were identified in most of PSA-screened prostate cancers.
|
18422767 |
2008 |